FORA Capital’s Viking Therapeutics VKTX Stock Holding History

FORA Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,115	Closed	-$268K	–	714
2025 Q1	$268K	Sell	11,115 -16,629	-60%	-$526K	0.03%	414
2024 Q4	$1.12M	Buy	+27,744	New	+$1.58M	0.13%	188
2024 Q3	–	Sell	-31,139	Closed	-$1.65M	–	591
2024 Q2	$1.65M	Sell	31,139 -42,772	-58%	-$2.8M	0.2%	163
2024 Q1	$6.06M	Buy	+73,911	New	+$3.29M	0.5%	61
2020 Q1	–	Sell	-14,168	Closed	-$114K	–	1365
2019 Q4	$114K	Buy	+14,168	New	+$103K	0.01%	733

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

FORA Capital's VKTX Position: Q2 2025 in Review

FORA Capital sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 11,115 shares — an estimated $268K sold.

FORA Capital first reported a position in VKTX in Q4 2019 and held it in 5 quarters. The position peaked at $6.06M in Q1 2024. 392 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

FORA Capital reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
FORA Capital sold 11,115 Viking Therapeutics shares in Q2 2025, an estimated $268K.
FORA Capital first reported a position in Viking Therapeutics in Q4 2019 and held it in 5 quarters.
FORA Capital's Viking Therapeutics position peaked at $6.06M in Q1 2024.
392 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on FORA Capital's 13F filing for Q2 2025, filed 13 Aug 2025.